📋 Tender Overview
Grant agreement ID: 101120108
DOI
10.3030/101120108
EC signature date
11 July 2023
Start date
1 January 2024
End date
31 December 2027
Rare diseases, often of genetic origin, affect millions worldwide, yet most have no cure or effective treatment. This is particularly true for cystic fibrosis (CF) and cystinosis, two severe paediatric disorders that manifest early in life. While CF research has advanced, leading to new drug developments, cystinosis remains a major clinical challenge. Innovative approaches are needed to bridge the gap between research and personalised therapies. Supported by the Marie Sklodowska-Curie Actions programme, the ORGESTRA project is harnessing the power of stem cell-derived organoids to develop new treatment strategies. By training doctoral candidates across disciplines, ORGESTRA aims to identify druggable targets, and create a living-technologies toolset to accelerate clinical applications.
